Based in Charlotte, North Carolina, SonaCare Medical is dedicated to advancing focused ultrasound in the treatment of disease. In 2015, SonaCare’s Sonablate earned US Food and Drug Administration authorization for the ablation of prostate tissue. This ruling has enabled patients with prostate conditions, including cancer and benign prostatic hyperplasia (BPH), to have access to noninvasive focused ultrasound therapy.
At the event, Sonacare’s Karen Cornett and Ralf Seip demonstrated the focused ultrasound technology behind Sonablate. Their display used focused ultrasound beams generated by Sonablate that were targeted at the top of a small tank of water. At the focal point of the beams, a fountain of water and vapor was created at the surface of the water that could be seen spraying into the air above the tank.
This showcase comes on the heels of a successful fly-in event last month in which representatives from Sonacare and various other focused ultrasound companies joined patients and physicians to educate policymakers on Capitol Hill about this revolutionary technology.
“SonaCare was delighted to have the opportunity to present at this notable event and to participate in the fly-in,” said Dr. Mark Carol, CEO of SonaCare. “The Focused Ultrasound Foundation, responsible for sponsoring our application to display and for helping to organize the fly-in, has been a great partner not only to the field of focused ultrasound in general but to SonaCare specifically. We look forward to continued opportunities to work together in the future.”
Other notable companies that took part in the Innovation Showcase include Fitbit, IBM, Uber Health, and Walgreens.